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Abstract 
The management of inflammatory rheumatic diseases during pregnancy and breastfeeding has 
undergone considerable change in the past few years. Modern therapeutics, including biologic and 
targeted synthetic DMARDs, have enabled substantial improvements in control of rheumatic 
diseases, resulting in more patients with severe disease considering pregnancy. Therefore, 
management of disease for these patients needs to be discussed with clinicians before, during and 
after pregnancy and patients need to know what complications they might experience before they 
become pregnant. This Review will summarize the effects pregnancy has on various rheumatic 
diseases and the effects these diseases have on pregnancy, as well as provide advice regarding the 
alteration and monitoring of therapy before, during and after pregnancy.  
 
 
[H1] Introduction  
Inflammatory rheumatic diseases, which include systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA), other inflammatory arthropathies, axial spondyloarthritis, primary Sjögren syndrome, 
systemic sclerosis (SSc) and primary systemic vasculitis, can affect women of childbearing age (Box 1) 
1-5. In this context, SLE and various inflammatory arthropathies have been studied the most and are 
associated with an increased burden of adverse pregnancy outcomes (APOs), such as miscarriage, 
maternal hypertension, intrauterine growth restriction and/or premature delivery. These women 
often have disease that is being controlled by use of DMARDs and they are, therefore, increasingly 
considering pregnancy as a possibility 6.  
 
Management of pregnancy in women with rheumatic diseases is affected by various factors. Active 
disease is associated with APOs 6, hence DMARDs are required during pregnancy to ensure control of 
maternal disease and satisfactory pregnancy outcomes. However, prescription of many DMARDs is 
complicated by safety concerns and evidence-based guidelines are unable to provide reliable 
evidence-based recommendations for all drugs 7-9. Specific pregnancy concerns exist for various 
conditions that should be considered when discussing pregnancy planning and disease management 
with patients.  
 
Conversations between clinicians and patients with rheumatic diseases are vital to ensure the 
patient understands the potential effects of the timing of conception (with respect to disease 
activity), of disease upon pregnancy, and of pregnancy upon disease, and the potential need for 
medication alterations that might be required in relation to pregnancy and breastfeeding. [Au:OK?]  
 
This Review focuses on pregnancy planning in patients with RA, SLE, psoriatic arthritis (PsA), 
spondyloarthritis, primary Sjögren syndrome or SSc. Pregnancy in patients with primary systemic 
vasculitis is rare; advice specific to this disease is beyond the scope of this article but it is managed 
similarly to SLE.  
 
 
 
[H1] Timing of pregnancy  
Patients with inflammatory rheumatic diseases should conceive during a period of disease 
quiescence to reduce the risk of disease flare in pregnancy 6,9,10. In patients with well-controlled 
disease that lacks extra-articular manifestations and organ dysfunction, a 3-month period of disease 
control on stable medications compatible with pregnancy should suffice, but the precise duration of 
this period of quiescence is a matter of debate. In SLE, the risk of disease flare during pregnancy is 
increased in patients with: active disease within 4–6 months before conception 11,12;, in patients with 
active disease at conception 13,14;, and following discontinuation of hydroxychloroquine (even when 
disease is quiescent) [Au:OK?] 15,16. EULAR recommends 6–12 months of disease quiescence is 
needed prior to conception dependent on various maternal factors, such as degree of residual organ 
dysfunction 17.  
 
[H1] Effect of disease on pregnancy  
[H2] Fertility and parity  
 Patients with inflammatory rheumatic diseases have fewer children than other 
women6,18Explanations for this phenomenon include physical disability 19, renal failure 20, teratogenic 
medications 21, depression or fatigue that can lead to reduced libido or sexual dysfunction in women 
22, and increasing maternal age associated with reduced ovarian reserves and oocyte quality 23 
(reviewed elsewhere 24). In particular, cyclophosphamide-induced gonadal toxicity [G] is a 
substantial problem for patients with severe rheumatic disease 21,24, and strategies have been 
developed to safe-guard against fertility loss before treatment with cytotoxic drugs 25. These 
strategies include semen cryopreservation, embryo or oocyte cryopreservation, and the use of 
gonadotropin-releasing hormone analogues or agonists to suppress ovarian function and utero-
ovarian blood flow [Au:OK?] in order to reduce exposure to gonadotoxic drugs such as 
cyclophosphamide. However, the use of gonadotropin-releasing hormone analogues is controversial 
and data from randomised trials of their use in patients receiving chemotherapy for different 
cancers are inconsistent 25. 
 
[H2] Risk of adverse pregnancy outcomes  
An increased burden of APOs has been reported in various inflammatory rheumatic diseases, 
described below and in Table 1. Various retrospective studies have shown that women with RA 
have an increased risk of hypertensive disorders of pregnancy (gestational hypertension [G] and 
preeclampsia [G] ), intrauterine growth restriction [G] (IUGR), premature delivery, caesarean 
delivery and increased length of hospital stay for pregnancy in population studies that included 
>3,500 patients with RA 26-29. Although a smaller retrospective cohort study (243 women with RA 
[Au:OK?])_also confirmed an increased risk offor prematurity and caesarean section, an 
approximately 50% increased risk of hypertensive disorders of pregnancy and reduced fetal 
growth in patients with RA was not statistically significant as compared with population controls 
in one study      30. In other small (up to 150 patients) prospective studies of pregnancy in 
patients with RA, the risk of hypertensive disorders was increased in one study 31, but not in two 
others 10,32. Overall, given the consistent finding of an increased risk of hypertensive disorders in 
RA pregnancy from large population studies it would seem prudent to counsel women with RA 
about this risk. 
In SLE, several large (mostly retrospective) population-based studies of a total >15,000 pregnancies 
in patients with SLE have identified an increased risk of hypertensive disorders of pregnancy, pre-
term labour and IUGR 14,33-36. In addition, a meta-analysis including studies published 2001–2016 
(including 3,395 patients with SLE) confirmed an increased risk of a range of maternal and fetal 
APOs, including hypertension (relative risk (RR) 1.99), preeclampsia ( (RR 1.91), pre-term labour (RR 
3.05), IUGR (RR 4.44) and small for gestational age [G] (RR 1.69) 37.  
 
High disease activity immediately prior to and during pregnancy is clearly linked with APOs in RA 
and SLE 10,38,39. A cohort study of pregnancy in patients with axial spondyloarthritis found an 
increased risk of APOs in these patients compared with healthy individuals [Au:OK?] as well as 
an association between active disease and preterm delivery 31. 
 
The effect of other inflammatory rheumatic diseases on pregnancy outcome is not well 
characterised. Pregnancy in PsA does not seem to be associated with APOs 40,41. Case–control 
studies have shown an increase in the rates of spontaneous abortion, preterm deliveries and 
caesarean section in pregnancies in women with primary Sjögren syndrome pregnancies 
compared with those in healthy individuals 42. A high frequency of pre-term births and small full-
term infants has been shown to occur in patients with SSc, with no difference in the frequency of 
miscarriage and neonatal survival compared with healthy individuals 43. 
 
[H1] Effect of pregnancy on disease 
[H2] Remission and relapse in pregnancy 
Reports of reduced improvement in disease activity in as many as 90% of RA pregnancies come 
mostly from retrospective studies that do not reflect current practice, in as the use of biologic 
therapies that now enables many women with severe disease to become pregnant [Au: wording 
OK?]      6,44. Studies using validated measures of disease activity, such as the 28-joint Disease Activity 
Score for RA, found less convincing evidence that pregnancy reduces disease activity, with only 48–
60% of women with active RA showing signs of reduced disease activity during pregnancy and 39–
50% having a disease flare within 6 months post-partum 45.  
 
The effect of pregnancy on SLE disease activity is unclear as some studies have reported no 
increased risk of SLE flares during pregnancy, compared with non-pregnant patients with SLE 13,46,47, 
whereas other studies show pregnancy is associated with an increased SLE flare rate 48-50. These 
results are conflicting, possibly because of small cohort sizes and the use of varying methodologies 
to assess disease activity and define disease flares, but a systematic review calculated an overall 
flare rate (mostly mild flare) of ~25% and a severe flare rate of ~5% 51. These flare rates were 
obtained from a meta-analysis of 1,842 patients with SLE with 2,751 pregnancies between them, 
including patients with lupus nephritis 35 and the prospective PROMISSE (Predictors of Pregnancy 
Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) 
study of 385 SLE pregnancies 34. In the PROMISSE study, 12.7% had a mild or moderate flare and 
2.5% had a severe flare at 20 to 23 weeks, plus 9.6% had a mild or moderate flare and 3.0% had a 
severe flare at 32 to 35 weeks 34. A single-centre observational study 52, which was not included in 
the meta-analysis 35, of 398 pregnancies in 304 patients with SLE and 1,045 non-pregnant patients 
with SLE reported an increased flare rate in pregnancy (hazard ratio (HR) 1.59; 95% CI 1.27–1.96) 
that was reduced by hydroxychloroquine therapy (HR 1.26 (95% CI 0.88–1.69) in 
hydroxychloroquine-treated patients, compared with HR 1.83 (95% CI 1.34–2.45) in those who were 
not treated with hydroxychloroquine). 
 
Information on disease activity and pregnancy outcomes in women with other inflammatory 
rheumatic diseases is limited. Some studies show that disease course and severity are not altered by 
pregnancy in axial spondyloarthritis 53,54 and similar data are conflicting for PsA 40,41,55.  
 
[H2] Presence of autoantibodies 
Anti-SSA/Ro and anti-SSB/La antibodies are usually detected in patients with SLE and primary 
Sjögren syndrome, are uncommon in RA and are sometimes detected incidentally in patients who 
lack other features of autoimmune disease 56. Around 16 weeks gestation, these antibodies cross the 
placental barrier by active transplacental transfer (Figure 1). This process involves engagement of 
the Fc region with neonatal Fc receptors on syncytiotrophoblast cells 57 and has a number of 
implications for the fetus and newborn. The most important risk is that of atrioventricular block 
(AVB), with congenital complete heart block occurring in 1–2% of babies born to anti-SSA/Ro positive 
mothers with no previously affected pregnancies, known as neonatal lupus syndrome. This risk      
[Au: do you mean risk of CHB? Or of AVB?] increases to ~17 % if previous pregnancies have resulted 
in AVB 58. Less common      [Au: less common than CHB? or than AVB?] in children born to mothers 
who are positive for anti-SSA/Ro antibodies is late-onset cardiomyopathy leading to congestive 
cardiac failure58. In three case reports anti-SSA/Ro positivity and anti-SSB/La positivity have also 
been associated with endocardial fibroelastosis [G] , which has a poor cardiac prognosis including 
end-stage heart failure and death and can occur in the absence of AVB 59 . Other features of 
neonatal lupus syndrome include a transient subacute cutaneous lupus rash exacerbated by UV 
exposure after birth, haematological manifestations (such as cytopenias) and hepatobiliary disease 
60. Most of these manifestations resolve in the first 6–9 months of life as maternal anti-SSA/Ro 
antibodies are cleared from the baby’s circulation 60 . 
 
Persistent positivity for anti-phospholipid antibodies (aPL) identifies individuals at risk of various 
specific APOs (one or more unexplained deaths of a morphologically normal fetus at ≥10 weeks 
gestation; one or more premature births of a morphologically normal neonate before 34 weeks 
gestation because of eclampsia, preeclampsia, or placental insufficiency [G] ; or three or more 
consecutive spontaneous pregnancy losses at <10 weeks gestation, unexplained by chromosomal 
abnormalities or by maternal anatomical or hormonal causes) and maternal thrombosis that 
characterise antiphospholipid syndrome (APS) 61,62. Common aPL are detected by lupus 
anticoagulant, anti-cardiolipin and anti-β2 glycoprotein 1 assays. Lupus anticoagulant positivity 
seems to be the strongest predictor of APOs in APS 34,63 and triple positivity for all three tests 
indicates an especially high risk of pregnancy complications and thrombosis 64,65 . The presence of 
aPL increases the risk of venous thromboembolism in patients with SLE two-fold for anticardiolipin 
positivity and six-fold for lupus anticoagulant positivity, compared with normal populations [Au: Do 
you mean ‘healthy individuals’? or patients with SLE negative for aPL?]    66. In patients without an 
underlying autoimmune disease, venous thrombotic risk is increased 1.5-fold for anticardiolipin 
positivity and up to 10-fold for lupus anticoagulant positivity 67,68, whereas arterial thrombosis is 
increased three-fold and four-fold, respectively 68. However, these estimates, derived from meta-
analyses, are limited by a lack of prospective data, small cohort size, lack of controls and variable aPL 
assay methodology amongst the source studies. Patients with a history of thrombotic APS have a 
lower live birth rate than those without thrombosis 65. A 2019 survey of data from the European 
Registry on Obstetric Antiphospholipid Syndrome 69, which studied 1,000 women with obstetric APS 
as defined by the 2006 Sydney classification criteria 61, has shown that the live-birth rate is only 
49.6% without treatment but rises to 85% with the recommended treatment regimen and to 72.4% 
with other regimens including low-dose aspirin or low-molecular-weight heparin (LMWH) but not on 
the recommended schedule. Recurrent miscarriages were observed before 10 weeks gestation in 
27%, fetal loss in 17% and stillbirth in 18.5% of this cohort of patients with obstetric APS. The survey 
also reported early preeclampsia (before 34 weeks gestation) in 18.1% and early IUGR (before 34 
weeks gestation) in 16.1% of the cases studied 69. 
 
 
[H2] Presence of organ dysfunction  
The presence of organ dysfunction as a complication of an inflammatory rheumatic disease greatly 
increases the prospect of maternal and fetal morbidity and mortality and should therefore be 
discussed during pregnancy planning. Conception should be delayed if a patient has active disease 
and organ dysfunction, until a period of disease quiescence and improvement or normalisation of 
organ function is achieved. For example, the presence (or even history) of active lupus nephritis at 
conception is a strong predictor of poor maternal and fetal outcomes 35,71. However, the risk 
associated with renal disease is not specific to patients with rheumatic disease and prospective 
studies involving women with chronic kidney disease of various aetiologies have demonstrated 
increased risks of pre-eclampsia, preterm delivery, small size for gestational age and increased infant 
and perinatal mortality rates 72-74. Furthermore, women with advanced chronic kidney disease (stage 
4–5) prior to pregnancy have an increased risk of an accelerated decline in renal function, potentially 
leading to end-stage disease and the need for renal replacement therapy either in pregnancy or 
shortly after 75. Other relative contraindications to pregnancy in patients with inflammatory 
rheumatic diseases that require multidisciplinary consultation and management include pulmonary 
hypertension 76, severe interstitial lung disease 77, advanced heart failure 78 and previous severe 
gestational hypertensive disorders despite therapy 79. 
 
[H1] Medication  
Predictive tests to stratify patients at risk of disease relapse and thus requiring intensification rather 
than withdrawal of therapy in pregnancy are lacking. Therefore, treatment decisions are made on 
the basis of the pattern of disease activity and manifestations and using standard laboratory markers 
of disease activity. Medications that are compatible with pregnancy therapy should be continued 
and intensified appropriately during pregnancy to ensure maintenance of disease control and reduce 
the risk of APOs (Figure 2). The British Society for Rheumatology (BSR) and EULAR have published 
guidance regarding the use of various anti-rheumatic drugs in pregnancy and breastfeeding 7-9. 
Evidence-based recommendations are summarised here and in Table 2.  
 
[H2] Glucocorticoids  
Glucocoticoids can be divided into non-fluorinated (such as prednisone, prednisolone, 
hydrocortisone and methylprednisolone) and fluorinated (such as dexamethasone and 
betamethasone) formulations. Non-fluorinated glucocorticoids are safe in pregnancy and 
breastfeeding as they are metabolised in the placenta with less than 10% of the active drug reaching 
the fetus 80. Titration to the minimum tolerable dose [G] of corticosteroid is required to reduce 
complications such as steroid-induced diabetes mellitus, hypertension and infections in the mother 
81. Glucocorticoids are associated with an increased risk of premature birth and some reports have 
suggested that this increased risk is independent of disease activity 10,82. Some studies in SLE have 
detected an association between these drugs and premature rupture of the amniotic sac (known as 
rupture of membranes) surrounding the baby 83, but other studies did not detect this association 84-
86. Fluorinated corticosteroids are not metabolised by the placenta and cross the placental barrier87, 
so these drugs should be used for fetal indications only. Dexamethasone has been suggested to 
cause developmental problems, such as delayed neuropsychiatric development 83, but this 
conclusion was not confirmed in two other cohorts of children born to anti-Ro/SSA antibody positive 
mothers88,89. In pregnancy, non-fluorinated corticosteroids are generally administered orally 
(prednisolone), whereas intravenous administration (for example, with methylprednisolone) is 
generally used as rescue therapy [G] for severe disease. Compared with prednisolone, parenterally 
administered methylprednisolone has a prolonged duration of action, with equivalent glucocorticoid 
(anti-inflammatory) effects at a lower dose (80% of prednisolone dose) and similar rates of trans-
placental transfer 7. 
 
[H2] Synthetic DMARDs  
A number of conventional synthetic DMARDs should be stopped prior to conception. Methotrexate 
is teratogenic and should be stopped 3 months before conception 7,9. Given that leflunomide was 
teratogenic in animal studies and has a long half-life, a cholestyramine washout to eliminate the 
drug from the body should be completed pre-conception, despite reassuring data from accidental 
exposures in human pregnancies90 . Mycophenolate mofetil is teratogenic and should be stopped 6 
weeks before conception 91. Cyclophosphamide is teratogenic and should be stopped at least 3 
months before conception 92 . 
 
Conventional DMARDs that can be continued during pregnancy include hydroxychloroquine, 
sulfasalazine, azathioprine and the calcineurin inhibitors ciclosporin and tacrolimus 7,9. Women who 
have conceived while being treated with leflunomide and then stopped this drug and undergone 
cholestyramine washout in the first trimester 90,93, or who have been exposed to leflunomide at 
various stages of pregnancy without washout 94,95, do not have an increased risk of APOs. Although 
leflunomide does not seem to be a major human teratogen, more data are required before its use 
during pregnancy can be safely advised.  
 
Targeted synthetic DMARDs (such as apremilast, tofacitinib and baricitinib) are small-molecule 
inhibitors that are increasingly being used to treat inflammatory rheumatic diseases 96-98. These 
drugs should be avoided during pregnancy until data are gathered on the risks associated with their 
use. The precise timing of when to stop these drugs before pregnancy is unclear, but given their 
short half-lives (3–12 hours 96-98), stopping each drug 1 month before conception should be 
sufficient.  
 
[H2] Biologic DMARDs  
Biologic DMARDs are recombinant proteins, usually either monoclonal IgG1 antibodies or fusion 
proteins containing the Fc portion of IgG1 joined to receptor-blocking proteins. These drugs share 
similar structure with maternal IgG, which are large proteins (~150 kDa) that are unable to diffuse 
across the placenta 99. Active trans-placental transfer of maternal IgG takes place via neonatal Fc 
receptors on syncytiotrophoblast 100-102 and occurs rapidly from 16 weeks of pregnancy onwards 100-
012 (Figure 1). Some biologic DMARDs are fusion proteins containing part or none of the IgG structure 
, principally etanercept and abatacept. Etanercept is a fusion protein of the soluble TNF receptor 2 
and the Fc region of IgG1a and despite the presence of the Fc region has low rates of trans-placental 
transfer 103,104. Anakinra is a recombinant human IL-1 receptor antagonist that does not contain any 
immunoglobulin structure, hence it lacks the Fc region, and has not been found to cross full-term 
human placenta 105. Abatacept contains the Fc region of IgG1 fused to the extracellular domain of 
CTLA-4 and has not yet been associated with any specific pattern of risk 106. Therefore, it is important 
to consider carefully both the structure and timing of biologic DMARD exposure during pregnancy. 
 
Current guidelines recommend that patients treated with TNF inhibitors should continue with these 
drugs through to the second or third trimester (depending on drug bioavailability based on the half-
life of the drug in the circulation, and on transplacental passage based on the structure of the TNF 
inhibitor). Administration of the TNF inhibitors is usually stopped at appropriate times in pregnancy 
(Table 3) to ensure that there is no TNF inhibitor in the maternal circulation at the time of birth as it 
would also be present in the baby and persist in the neonatal circulation, possibly putting the baby 
at risk of infection after administration of live vaccines 7,9. If there is a concern that an inflammatory 
rheumatic disease will flare, TNF inhibitors should be continued throughout pregnancy but live 
vaccines, such as rotavirus and tuberculosis, should be avoided in the exposed infant until 6 months 
of age. This advice is based on a case of fatal tuberculosis-like disease reported post-BCG vaccination 
in an infant who was not breastfed but was exposed throughout pregnancy to infliximab, a TNF-
inhibitor with a long half-life in infants 107. Certolizumab pegol, a PEGylated Fab′ that is specific for 
TNF, has minimal levels of transfer across the placenta 108 and into breastmilk 109, and is therefore 
licenced by the European Medicines Agency and Food and Drug Administration for use during 
pregnancy and breastfeeding.  
 
Current British and European guidelines recommend that other biologic DMARDs (such as rituximab, 
belimumab, anakinra, and tocilizumab) are stopped in advance of pregnancy owing to limited data 
7,9. However, some of these drugs (anakinra and tocilizumab) have been recommended for use 
during pregnancy if other treatment options are limited and the benefits of maintaining disease 
suppression with these biologic agents outweigh the risks 110,111.  
 
  
Increasingly, biosimilars are replacing existing originator biologic DMARDs. To date, published 
evidence on the use of biosimilars in pregnancy is very limited. Given their similarity to originator 
compounds in terms of identical molecular target and antibody structure with variation only in post-
translational modifications (as exists between different batches of existing originator biologic 
DMARDs), it seems reasonable to counsel patients regarding the use of biosimilars in pregnancy on 
the basis of the existing evidence for each originator compound.  
 
[H2] Analgesics 
Conventional NSAIDs are generally safe, but should be avoided in the third trimester owing to their 
effects upon the ductus arteriosus [G], namely the premature closure of this vessel leading to 
progressive right heart dysfunction, congestive heart failure and intrauterine death, and shouldbut 
can be used with caution [Au:OK?] in the first trimester owing to a low risk of miscarriage 8. 
However, cyclooxygenase-2-selective NSAIDs are not recommended because of a lack of data and 
the theoretical risks that these drugs could impair fertilisation, implantation and maintenance of 
pregnancy 112 . 
 
Codeine is compatible with pregnancy and during peri-conception for acute pain 8. British Society for 
Rheumatology guidelines state that no consistent evidence exists to recommend dose-reduction 
before delivery, but neonatologists should be aware of maternal use of codeine during 
breastfeeding, owing to the risk of central nervous system depression resulting from unpredictable 
metabolism of codeine to morphine8. 
 
Amitriptyline, gabapentin and pregabalin are commonly used to treat chronic pain. Amitriptyline is 
safe to use during pregnancy, but gabapentin or pregabalin are not recommended 8. 
 
[H2] Co-morbidity medications  
A review of the entire drug list prescribed to each patient is important to ensure that all medications 
prescribed for co-morbidities, particularly those commonly associated with inflammatory rheumatic 
diseases, are compatible with pregnancy. In the event of pregnancy, patients with pre-existing 
hypertension should be instructed to switch from angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers and chlorothiazide agents associated with congenital anomalies to 
alternative antihypertensive drugs, such as labetalol nifedipine or methyldopa 113. In addition, 
women at moderate or high risk of preeclampsia should avoid excessive dietary salt intake and 
should take low-dose aspirin 114,115. Patients receiving an ACE inhibitor to reduce proteinuria before 
pregnancy might have greater proteinuria as a result of stopping the ACE inhibitor and the increased 
glomerular filtration rate (of 50–80%) in pregnancy. Even in patients with diabetic nephropathy this 
change does not signify worsening renal disease and proteinuria often returns to baseline post-
partum 116. Warfarin is contraindicated in pregnancy owing to an increased risk of congenital 
abnormalities if continued after week 6 of gestation, so patients taking warfarin should switch to 
LMWH once pregnancy is confirmed 8.  
 
[H1] Management during pregnancy 
[H2] General principles 
  
Patients with inflammatory rheumatic diseases who are planning pregnancy or who are pregnant 
should be managed in a multidisciplinary setting with close obstetric and rheumatological 
monitoring, involving regular clinical, laboratory and obstetric ultrasound evaluations and the advice 
of other specialists depending on organ involvement. Risk stratification should be performed 
according to degree and extent of maternal disease as well as the antibody status of the patient 
(aPL, anti-SSA/Ro and anti-SSB/La antibodies). The overall goal is to develop an individualised plan 
for management to suppress disease activity using a treat-to-target approach during pregnancy to 
optimise the chance of a successful pregnancy outcome (Figure 3).  
 
[H2] Maintenance and monitoring of disease control 
Disease control is maintained by continued prescription of medications that are compatible with 
pregnancy. For patients with inflammatory arthritis, sulfasalazine and hydroxychloroquine are ideal 
maintenance therapies 7,9 and with the caveats already discussed biologic DMARDs might be 
considered. In patients with SLE, hydroxychloroquine is a mainstay of treatment and discontinuation 
of this drug is associated with an increased risk of flares and APOs in pregnancy 15,16,52. Other suitable 
DMARDs include azathioprine, ciclosporin and tacrolimus 7,9.  
 
 
Glucocorticoids can be used to treat any inflammatory rheumatic disease, particularly to treat 
disease flares, and should be titrated to the minimum tolerable dose to maintain disease control and 
limit steroid related side-effects such as hyperglycaemia and bone loss 17,81. Concomitant use of 
calcium and vitamin D to the end of lactation is also particularly important for patients treated with 
glucocorticoids and/or heparin as they are at increased risk of osteoporosis 17,117. All pregnant 
patients with SLE at high risk of pre-eclampsia, including those with lupus nephritis or positive for 
aPL, should be treated with low-dose aspirin (≤150mg daily), which has been shown to reduce the 
risk of pre-eclampsia in non-SLE high-risk pregnancies 17,118.  
 
When monitoring disease activity in pregnancy, awareness of physiological changes of pregnancy 
that resemble those of disease flare is important. Examples of such changes include proteinuria (up 
to 300 mg per day), increased erythrocyte sedimentation rate (up to 70 mm/h), a 2–3-fold rise in 
serum complement concentrationslevels or a fall in serum haemoglobin concentrationslevels [Au: 
change to ‘serum concentrations’ OK?] (<110g/l) 119. In addition, increasing degrees of back pain 
and swelling of the hands, feet and knees are common in late pregnancy and could be mistaken for 
arthritis flare. Therefore, C-reactive protein is a more accurate indicator of inflammation than 
erythrocyte sedimentation rate in pregnancy 119 and should be used in this situation for monitoring, 
except in SLE for which any fall in complement (C3 or C4) of ≥25% is important, even if into the 
‘normal’ range 17 . 
 
For most inflammatory rheumatic diseases, the same outcome assessment for non-pregnant 
patients is used during pregnancy, but the use of modified disease activity scores is recommended in 
some conditions. For example, a modified 28-joint disease activity score for RA includes a measure 
of C-reactive protein (DAS28-CRP) and unlike the standard DAS28 lacks the global health score, 
which can be affected by pregnancy itself 45 . Due to the complexity of SLE assessment in pregnancy, 
a disease activity index has been developed and validated by modifying the British Isles Lupus 
Assessment Group (BILAG2004) to create the BILAG2004-Pregnancy index so that physiological 
changes of pregnancy do not influence the score 120. 
 
[H2] Monitoring for pregnancy complications 
Women with inflammatory rheumatic diseases should seek antenatal care early (before 12 weeks of 
pregnancy ) and this care should be managed in a multidisciplinary setting. In addition to routine 
pregnancy monitoring, clinical assessment of the mother and the baby should include measurement 
of blood pressure, urinalysis and blood tests, such as for autoantibody status and disease activity. In 
addition, obstetric ultrasound scans are required at specified intervals to record fetal anatomy, 
growth and development as recommended for healthy pregnancy with additional monitoring in the 
third trimester for SLE and APS pregnancies 17,69. 
 
[H2] Prevention and treatment of pre-eclampsia 
There is an increased risk of pre-eclampsia in patients with inflammatory rheumatic diseases, 
particularly in patients with SLE, previous renal disease or patients treated with concomitant 
glucocorticoids 14,17,33-36. Risk factors for pre-eclampsia and APOs in SLE pregnancy include high 
disease activity at conception and during pregnancy, a history of lupus nephritis, maternal 
hypertension, presence of aPL, low serum complement concentrationslevels and thrombocytopenia 
121. All patients with an increased risk of pre-eclampsia should be treated with low-dose aspirin until 
delivery 17,51. In addition, they should be monitored for development of pre-eclampsia, which 
includes measurement of blood pressure and proteinuriaurine protein      [Au: change from ‘urine 
protein’ to ‘proteinuria’ OK? Or should it be ‘urinalysis’?] at each visit and fetal ultrasound and 
uterine artery Doppler ultrasound [G] flow studies as ordered by obstetric consultants. Bilateral 
uterine notching [Au: do you mean ‘The presence of bilateral uterine notching’?] , indicating 
abnormal blood flow, between 23 and 25 weeks gestation can be used to predict early-onset 
preeclampsia and gestational hypertension 122. In addition, measurement of circulating angiogenic 
factors (including soluble Fms-like-tyrosine kinase 1, placental growth factor and soluble endoglin), 
which are dysregulated in preeclampsia in non-autoimmune pregnancies 123, can also be used to 
predict the risk of various APOs, including preeclampsia in patients with SLE 124. 
 
First-line treatment of hypertension in pregnancy is labetalol, with alternatives being methyldopa 
and nifedipine; ACE inhibitors, angiotensin II receptor blockers and chlorothiazide diuretics are 
associated with congenital malformations 125.  
 
Distinguishing between lupus nephritis and preeclampsia is challenging but important, as the 
management of these conditions is different 126. Both conditions are characterised by proteinuria, 
oedema, renal impairment, hypertension and thrombocytopenia. Indicators of lupus nephritis 
include falling (or failure to rise of) C3 and C4 levels, a rising titre of antibodies specific for double-
stranded DNA, active urinary sediment and other clinical indicators of SLE activity, such as skin 
disease, arthritis and cytopenia 126 . Anti-C1q antibodies are also associated with renal involvement 
in SLE 127 and might therefore function as a biomarker of active SLE. By contrast, many of these 
features are lacking in pre-eclampsia and unlike lupus nephritis, in pre-eclampsia C3 and C4 levels 
often increase 126 . If these tests are indecisive a renal biopsy is required to differentiate between 
lupus nephritis and pre-eclampsia. Depending on the clinical circumstances and the gestation of the 
pregnancy, premature delivery of the fetus might be mandated as the only cure for pre-eclampsia is 
delivery of the baby and potent immunosuppression cannot be given for serious renal lupus flare 
until after delivery due the increased risk of adverse events that would affect the mother and baby 
in this situation. Multi-disciplinary care is critical in this situation as inappropriate management 
could result in the death of the baby and/or mother 118,129. 
  
[H2] Thromboprophylaxis and anticoagulation 
Pregnancy itself is a pro-coagulant state with alterations in both coagulation and fibrinolysis, 
presumably to reduce blood loss at delivery 119, and this procoagulant risk is increased in various 
inflammatory rheumatic diseases 130 , particularly APS 61,63,69 . Thromboprophylaxis [G] is required 
with therapeutic anticoagulation in APS and is a consideration with anti-platelet therapy   [Au: do 
you mean it should be considered for patients receiving antiplatelet therapy in other conditions?] 
in other conditions, principally SLE 17,63,69 . Treatment to prevent recurrent early miscarriage is the 
only management in obstetric APS supported by clinical trial data 63,69 . Dual treatment with low-
dose aspirin and LMWH is the standard-of-care for all patients with APS. Warfarin is contra-indicated 
in pregnancy due to its teratogenic effects and patients being treated anticoagulated with this 
anticoagulant drug   [Au: changed from ‘anticoagulated’, OK?] should be switched to a therapeutic 
dose of LMWH once pregnancy is confirmed 8. Evidence is lacking regarding the safety of the direct 
oral anticoagulants apixaban, rivaroxaban, dabigatran and fondaparinux in pregnancy and use of 
these drugs is therefore not recommended 131.  
 
[H2] Anti-SSA/Ro and anti-SSB/La complications 
Using fetal cardiac ultrasound [G] , screening for congenital heart block [G] in pregnancies of anti-
SSA/Ro-positive and/or anti-SSB/La-positive mothers with a previously affected child should begin at 
16 weeks of pregnancy 17. For anti-SSA/Ro-positive and/or anti-SSB/La-positive women with no 
previous congenital heart block, most fetal cardiologists recommend an initial fetal cardiac 
ultrasound scan at 16–20 weeks with a repeat at 28 weeks if the initial scan is normal. Once 
established, complete AVB is irreversible and cardiac pacing [G] is almost always required, but 
specialist management of any associated cardiac disease might improve fetal outcome 132. 
Fluorinated glucocorticoids have been used to treat early stages of AVB 133 , but the benefit of this 
therapy has not been proven. Hydroxychloroquine, however, is associated with a reduction in the 
rate of recurrent AVB in future pregnancies after an affected pregnancy 134 and a lower rate of AVB 
in babies born to mothers with anti-SSA/Ro antibodies with or without SLE 135,136. Non-cardiac 
neonatal lupus manifestations are transient 137 and specific treatment is not required .  
  
[H2] Management of flares and organ dysfunction 
  
Standard management of inflammatory rheumatic disease flares in pregnancy is to treat with 
systemic glucocorticoids and add other DMARDs depending upon the disease and type of 
manifestation (Figure 2). In inflammatory arthritis, addition of sulfasalazine and/or 
hydroxychloroquine is suitable to maintain disease control 7,9 . For connective tissue disease or 
vasculitis, azathioprine is preferred 7,9 and in the case of lupus nephritis or cytopenia, tacrolimus can 
be used alone or in combination with glucocorticoids and/or other DMARDs in pregnancy 138 . In the 
case of severe maternal inflammatory rheumatic disease, intravenous immunoglobulins and plasma 
exchange might be therapeutic 139,140 ; premature delivery of the fetus should also be considered, to 
reduce the adverse consequences of chronic intrauterine asphyxia that can arise from impaired 
placental function caused by maternal disease 141.  
 
[H1] Post-partum management  
[H2] Risk of post-partum flare 
Post-partum inflammatory rheumatic disease flares are common but vary considerably in severity 
and timing, from several days to 3–6 months after delivery 45,46,52,54. Evidence that increasing the 
dose of glucocorticoids will prevent flare does not exist, but it is possible that flares are worsened by 
patients discontinuing therapy for fear of harming their baby when breastfeeding. 
 
[H2] Drugs and breastfeeding 
Drugs that can be used in pregnancy are usually compatible with breastfeeding, but few trials have 
tested this compatibility (Table 4). Certolizumab pegol is the only TNF inhibitor licensed by the 
European Medicines Agency and Food and Drug Administration for use during breast-feeding as it 
has minimal transfer into breast milk 109. Most inflammatory rheumatic disease flares   [Au: meaning 
flares during breastfeeding? Or in general?] are treated by starting or increasing the dose of existing 
oral prednisolone or intramuscular methylprednisolone 126 . Hydroxychloroquine is compatible with 
pregnancy and, although it enters the breast milk 7,9,142 , evidence does not exist that this drug can 
harm the baby. Similarly, sulphasalazine is commonly used by mothers with various inflammatory 
conditions. However, 5mg daily folic acid should be taken during pregnancy and breastfeeding to 
prevent folate deficiency in the baby 7. Patients treated with LMWH in pregnancy should continue 
this drug for 6 weeks post-partum 143 and patients previously taking warfarin can re-start this drug 
during breastfeeding 8, 143 The safety of the direct oral anticoagulants (such as apixaban, rivaroxaban, 
dabigatran and fondaparinux) during breastfeeding is unknown and these drugs are therefore not 
recommended during breastfeeding131. 
 
[H2] Contraception 
Contraception should be discussed soon after delivery for women with inflammatory rheumatic 
diseases and at risk of post-partum flare to ensure that they do not have a further pregnancy that is 
unplanned 17. Many women still think that breast-feeding will protect them from further pregnancy . 
The most appropriate contraception method is probably the method they used before pregnancy. 
An intrauterine device, such as a hormone-releasing coil, is a viable and safe option for a patient to 
consider and discuss with their general practitioner. Risk of infection is low in women using 
intrauterine devices and DMARDs, except in individuals whose behaviour, independent of their 
disease and its treatment, puts them at increased risk. 
 
 
[H1] Conclusions  
Pregnancy in patients with inflammatory rheumatic diseases has the best outcomes if women 
conceive during disease remission and with appropriate therapy. Persistent disease activity and 
disease flares in pregnancy are associated with an increased risk of IUGR, having babies that are 
small for gestational age and premature delivery. During pregnancy, screening and managing active 
disease and the increased risk of pre-eclampsia are important, particularly in patients with a history 
of hypertension, RA or SLE (especially lupus nephritis and APS). Women with inflammatory 
rheumatic diseases require specific advice about drug therapy while trying to conceive, during 
pregnancy and while breastfeeding and should be aware of the risk of post-partum flares. However, 
with careful planning, monitoring and treatment, most women with these diseases can have 
successful pregnancies. 
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Key points 
• Various inflammatory rheumatic diseases carry an increased burden of adverse pregnancy 
outcomes (APOs). 
• Pregnancy can exacerbate some but not all inflammatory rheumatic diseases.  
• Pre-pregnancy counselling is required to evaluate and reduce risks of APOs [Au:OK?] for 
each patient. 
• Some therapies must be altered before, during and/or after pregnancy. 
• Careful monitoring is required throughout pregnancy by a multidisciplinary team. 
• Vigilance for disease flare is required post-partum . 
  
 
Box 1. Prevalence of inflammatory rheumatic diseases in women of child-bearing age (per 100,000) 
Rheumatoid arthritis 
 120 (age 16 to 44) 1 
SLE 
 80 (age 20 to 49) 3 
Psoriatic arthritis 
 130 (age 18 to 49) 3 
Axial spondyloarthritis 
 117 (age 15 to 44) 4 
Sjogren’s syndrome 
 Data unavailable but probably low as it usually occurs after age 40 
Systemic sclerosis 
 7.0* (age 16–39) 5 
Primary systemic vasculitis 
 Data unavailable but probably low as onset usually occurs after age 40 
 
 
*Estimated from aggregated male and female prevalence of 8.4, given 83% of patients with SSc are 
female.  
 
 
 
Figure 1: Transplacental transfer of IgG antibodies from maternal blood into the fetal circulation. 
Antibodies such as anti-SSA/Ro and anti-SSB/La cross the placental barrier by active transplacental 
transfer via Fc receptor expressed on neonatal syncytiotrophoblast cells. Antibody transfer can have 
implications for the fetus and baby, including neonatal lupus syndrome. Maternal antibodies are 
cleared from the baby’s circulation within the first 6–9 months of life.  
  
Figure 2. Treat-to-target strategy for management of inflammatory rheumatic diseases in pregnancy.  
Treatment during pregnancy aims to maintain disease control and reduce the risk of adverse 
pregnancy outcomes. Medications that are compatible with pregnancy should be continued and 
intensified appropriately during pregnancy in case of disease flare. Appropriate treatment depends 
on the disease and type of manifestation.  
APS, antiphospholipid syndrome; IVIG, intravenous immunoglobulins; LMWH, low-molecular-weight 
heparin; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus. 
 
Figure 3. Optimisation of management of inflammatory rheumatic diseases in pregnancy. 
For patients with inflammatory rheumatic diseases, the chance of a successful pregnancy outcome is 
optimised by the development of an individualised plan to suppress disease activity using a treat-to-
target approach. Patients who are planning pregnancy or who are pregnant should be managed in a 
multidisciplinary setting with close obstetric and rheumatological monitoring, with risk stratification 
according to the degree and extent of maternal disease as well as the antibody status of the patient.  
APS, antiphospholipid syndrome; AVB, atrioventricular block. 
Table 1. Considerations for rheumatic diseases in pregnancy 
Disease  Disease activity  
during and after 
pregnancy  
Adverse pregnancy 
outcomes  
Risk factors for adverse 
pregnancy outcomes  
Rheumatoid 
arthritis 
~48–60% reduction 
during pregnancy  
~39–50% flare rate 
post-partum 45,46 
Pregnancy-induced 
hypertension, IUGR, pre-
term birth, small for 
gestational age, low 
birthweight 26-31 
Active disease at 
conception and during 
pregnancy  
Psoriatic arthritis  ~40-50% reduction 
during pregnancy  
Variable flare rate 
post-partum  
40,41,55 
No increased risk 40,41 N/A  
Axial 
spondyloarthritis  
~80% active/ and 
stable [Au:OK?] during 
pregnancy and post-
partum, with 
exacerbation most 
likely in the second 
and third trimesters        
 53,54 
Pre-term birth, small for 
gestational age, 
emergency or elective 
caesarean section 31 
Active disease at 
conception and during 
pregnancy  
SLE  ~25% flare rate in 
pregnancy  
51 
Pregnancy loss, 
pregnancy-induced 
hypertension, IUGR, pre-
term birth, small for 
gestational age, low 
birthweight, caesarean 
section, congenital heart 
block, neonatal lupus 14,33-
37 
Active disease at 
conception and during 
pregnancy, 
hypertension, lupus 
nephritis, APS, anti-
SSA/Ro antibodies, anti-
SSB/La antibodies 
APS  ~2–10-fold increased 
risk of thrombosis in 
pregnancy and post-
partum 66 
Pregnancy loss, 
pregnancy-induced 
hypertension, IUGR, pre-
term birth, caesarean 
section  
Antiphospholipid 
antibodies (particularly       
triple positivity for aCL, 
anti-β2GP1 and lupus 
anticoagulant) 
Sjögren 
syndrome  
N/A  Congenital heart block, 
neonatal lupus, pregnancy 
loss, pre-term birth, 
caesarean section 42 
Anti-SSA/Ro antibodies, 
anti-SSB/La antibodies 
Systemic 
sclerosis  
N/A  Pre-term birth, small for 
gestational age 43 
Rapidly progressive 
diffuse disease  
 APS, antiphospholipid syndrome; aCL, anticardiolipin antibodies; anti-β2GP1, anti-β2 glycoprotein-1 
antibodies; IUGR, intrauterine growth restriction; SLE systemic lupus erythematosus.  
 
 
Table 2. Anti-rheumatic drugs recommended by BSR and EULAR for use at conception and during 
pregnancy 7-9 
Drug class Compatible with pregnancy Some evidence of 
lack of harm  
 Contraindicated 
Analgesic Conventional NSAIDs (up to 
32 weeks of pregnancy), 
amitriptyline, opiates 
 N/A  COX2 inhibitors, 
gabapentin, pregabalin 
Anti-thrombotic Low-dose aspirin, heparin N/A  Warfarin, apixaban, 
rivaroxaban, dabigatran, 
fondaparinux 
Glucocorticoids  Glucocorticoids N/A N/A 
Conventional 
DMARDs 
Hydroxychloroquine, 
sulfasalazine, azathioprine, 
tacrolimus, ciclosporin 
Leflunomide  Methotrexate, 
 cyclophosphamide, 
 mycophenolate mofetil 
Biologic DMARDs  Certolizumab pegol, 
infliximab, adalimumab, 
etanercept, golimumab 
Anakinra, 
canakinumab, 
tocilizumab, 
abatacept 
Rituximab, belimumab, 
ustekinumab, rilonacept 
 
Targeted synthetic 
DMARDs 
N/A N/A Apremilast, tofacitinib, 
baricitinib 
BSR, British Society for Rheumatology; COX2, cyclooxygenase 2.  
 
 
Table 3. TNF inhibitors used during pregnancy 
TNF inhibitor Half-life Recommended discontinuation time during pregnancy 7,9 
Infliximab 8–9.5 
days 
16–20 weeks 
Etanercept 70 hours 24–32 weeks 
Adalimumab 14 days 20–24 weeks 
Certolizumab 14 days Safe throughout pregnancy 
Golimumab 12 days Limited data available; possibly safe in first trimester 
 
 
 
Table 4. Anti-rheumatic drugs recommended by BSR and EULAR for use during breastfeeding 7-9 
Drug class Compatible with 
breastfeeding 
Consider if benefits 
outweigh potential 
risks 
 Contraindicated 
Analgesic Conventional NSAIDs, 
Amitriptyline  
Opiates  N/A 
Anti-thrombotic Low dose aspirin, 
heparin, warfarin 
 N/A   Apixaban, rivaroxaban, 
dabigatran, 
 fondaparinux 
Glucocorticoids Glucocrticoids N/A  N/A 
Conventional DMARDs Hydroxychloroquine, 
sulfasalazine, 
azathioprine, 
tacrolimus, ciclosporin  
N/A  Methotrexate, 
cyclophosphamide, 
 mycophenolate mofetil 
Biologic DMARDs  Certolizumab pegol, 
infliximab , 
adalimumab, 
etanercept, 
golimumab  
Anakinra, 
canakinumab,  
abatacept, tocilizumab,  
rituximab, belimumab, 
ustekinumab 
 N/A 
Targeted synthetic 
DMARDs 
N/A N/A  Apremilast, tofacitinib, 
baricitinib 
 
 
 
 
Glossary Terms 
  
Cyclophosphamide-induced gonadal toxicity – Gonadal damage induced by cyclophosphamide, 
leading to reduced ovarian function. 
Gestational hypertension – New-onset hypertension presenting after 20 weeks gestation without 
significant proteinuria. 
Preeclampsia - New-onset hypertension presenting after 20 weeks gestation with significant 
proteinuria. Indicative of maternoplacental dysfunction.  
Intrauterine growth restriction – Reduced fetal growth resulting in an estimated weight below the 
10th percentile for gestational age.  
Small for gestational age - Term used to describe a baby who is smaller than usual for the number of 
weeks of pregnancy. These babies usually have birthweights below the 10th percentile for 
gestational age.  
Endocardial fibroelastosis - A rare heart disorder of infants and children that is characterised by a 
thickening within the muscular lining of the heart chambers due to an increase in the amount of 
supporting connective tissue (inelastic collagen) and elastic fibres. 
Placental insufficiency - Failure of the placenta to deliver sufficient nutrients and oxygen to the fetus 
during pregnancy. 
Minimum tolerable dose of corticosteroid – The minimum dose required to maintain disease control 
and reduce complications such as steroid-induced diabetes mellitus, hypertension and infections in 
the mother. 
Rescue therapy – Treatment given after a patient has failed to respond to standard therapy. 
Ductus arteriosus - A blood vessel in the fetus connecting the main pulmonary artery to the proximal 
descending aorta, allowing most blood from the right ventricle to bypass the lungs. Premature 
closure of this blood vessel leads to progressive right heart dysfunction, congestive heart failure and 
intrauterine death. 
Uterine artery Doppler ultrasound – A technique used to measure uterine artery blood flow between 
mother and baby. 
Thromboprophylaxis – In this context, the prevention of thromboembolic disease by pharmacologic 
means. 
Fetal cardiac ultrasound – Technique used to evaluate the structure of the fetal heart. 
Screening for congenital heart block – The use of fetal cardiac ultrasound at 16–18 weeks of 
pregnancy in anti-Ro/SSA-positive mothers. 
Cardiac pacing –Technique used to regulate heart rate involving the fitting of a pacemaker. 
